- •PD-L1 immunoreactivity was found in 4 of 58 meningiomas including low and high grades.
- •PD-L1 may be seen in occasional low grade as well as high grade meningiomas.
- •Screening for PD-L1 may be warranted in more than just WHO grade III tumors.
The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies. Recent identification of PD-L1 expression in some types of cancer cells has raised the possibility that its inhibition of host immunosurveillance may be part of the mechanism. Thus, tumor cell PD-L1 might be a useful new target for chemotherapy in PD-L1- bearing tumors. Several a monoclonal antibodies against PD-L1 are now in use in the management of treatment refractory or metastatic non-small cell carcinoma of the lung, metastatic renal cell carcinoma, melanoma and other malignancies. The extent of PD-L1 expression is not established in meningiomas. Depending on the degree of expression, anti-PD-L1, might be an effective treatment for meningiomas. In this study, we used a monoclonal antibody, approved by the FDA for clinical screening to evaluate PD-L1 expression in a series of 58 meningiomas including 13 with bone, brain or dural invasion. PD-L1 immunoreactivity was detected in 1 of 31 grade I, 1 of 16 grade II and 2 of 11 WHO grade III meningiomas. PD-L1 was seen in 1 grade II tumor invading brain and 1 grade III tumor invading bone but was not at sites of invasion. In each case, immunoreactivity was scored as limited. The findings suggest anti-PD-L1 therapy might be worth evaluating in a select number of positive tumors but its overall applicability may be limited.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Clinical Neuroscience
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Epidemiology and etiology of intracranial meningiomas: a review.J Neurooncol. 1996; 29: 197-205
- Meningioma grading: an analysis of histologic parameters.Am J Surg Pathol. 1997; 21: 1455-1465
- The role of chemotherapy and targeted therapy in treatment of intracranial meningioma.Curr Opin Oncol. 2012; 24: 666-671
- Atypical meningioma; current management dilemmas and prospective clinical trials.J Neurooncol. 2015; 121: 1-7
- Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.Neurooncology. 2014; 16: 1547-1553
- Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.Cancer Invest. 2006; 24: 727-733
- Hydroxyurea for recurrent and radiation refractory high grade meningiomas.J Neurooncol. 2012; (107–315-321)
- IFN-a for recurrent surgery- and radiation refractory high-grade meningioma: a retrospective case series.CNS Oncol. 2013; 2: 227-235
- Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.Cancer Chemother Pharmacol. 2014; 73: 919-923
- Atypical and anaplastic meningiomas treated with bevacizumab.J Neurooncol. 2012; 109: 187-193
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Neuro Oncol. 2015; 17: 116-121
- Understanding the checkpoint blockade in lung cancer immunotherapy.Drug Discov Today. 2017; (1359; 6446)
- Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).Ther Adv Med Oncol. 2018; 10: 1-12
- PD1 signal transduction pathways in T cells.Oncotarget. 2017; 19: 113-123
- Tackling cancer resistance by immunotherapy: updated clinical impact and safety of pD-1/PD-L1 inhibitors.Cancers. 2018; 10: 1-17
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.J Immunother Cancer. 2018; 8: 1-18
- The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells.Neurooncology. 2013; 15: 1479-1490
- The microglial/macrophagic response at the tumour-brain border of invasive meningiomas.Neuropathol Appl Neurobiol. 2009; 35: 82-88
- Expression and prognostic impact of immune modulatory molecule PD-L1 in meningiomas.J Neurooncol. 2016; 130: 543-552
- Increased expression of the immune modulatory molecule PD-L1 (cD274) in anaplastic meningioma.Oncotarget. 2014; 6: 4707-4716
- Checkpoint inhibition in meningiomas.Immunotherapy. 2016; 8: 721-731
- Regression of intracranial meningioma following treatment with nivolumab; case report and review of the literature.J Clin Neurosci Case Rep. 2017; 37: 51-53
- Meningioma.in: Louis D.N. Ohgaki H. Wiestler O.D. Cavenee W.K. Ellison D.W. Figarella-Branger D. Perry A. Riifenberger G. von Deimling A. WHO classification of tumours of the central nervous system. WHO Press, Geneva, Switzerland2016: 232-245
- Programmed cell death ligand1 expression and tumor infiltrating lymphocytes in neurofibromatosis 1 and 2 associated tumors.J Neurooncol. 2018; 10: 1-8
- Association of PD-1, PD-1 ligands and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res. 2014; 20: 5064-5074
Published online: August 25, 2018
Accepted: August 13, 2018
Received: April 14, 2018
© 2018 Published by Elsevier Ltd.